Evidence map›Paper›PMID 33240396›Full record

ArticleTherapeutic advances in gastroenterology2020

Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease.

Ariela K Holmer, Robert Battat, Parambir S Dulai, Niels Vande Casteele, Nghia Nguyen, Anjali Jain, Ara Miralles, Jennifer Neill, Helen Le, Siddharth Singh and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Ariela K HolmerInflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.ORCID https://orcid.org/0000-0003-0542-8439
Robert BattatInflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Parambir S DulaiInflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Niels Vande CasteeleInflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Nghia NguyenInflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Anjali JainPrometheus Biosciences, San Diego, CA, USA.
Ara MirallesInflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Jennifer NeillInflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Helen LeInflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Siddharth SinghInflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Jesus Rivera-NievesInflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
William J SandbornInflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Brigid S BolandInflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, #0956, La Jolla, CA 92093-0956, USA.
University of California San Diego · USCornell University · USPrometheus Biosciences (United States) · US

Funding

San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LARS ECKMANN, Bernd G. Schnabl · 2019 to 2026
$10.8M
Novel Traffic-targeted Therapies for IBDR01DK108670 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RIVERA-NIEVES, JESUS · 2016 to 2020
$3.3M
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel DiseasesK23DK117058 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2018 to 2022
$971k
USING SINGLE-CELL RNA AND PROTEIN APPROACHES TO ELUCIDATE MOLECULAR DETERMINANTSAND PREDICTORS OF INFLAMMATORY BOWEL DISEASESK23DK123406 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOLAND, BRIGID S · 2020 to 2022
$720k
Immunoprofiling for identifying biomarkers in celiac diseaseR21AI149636 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ERNST, PETER B., RIVERA-NIEVES, JESUS · 2020 to 2021
$433k
High Dimensional Mass Cytometry Analysis of the Effects of Vedolizumab in Intestinal Cellular Subsets and its Correlation with Clinical ParametersR21DK118927 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI RIVERA-NIEVES, JESUS · 2019 to 2020
$392k
BLRD VA I01 BX003436NIAID NIH HHS R21 AI149636NIDDK NIH HHS K23 DK117058NIDDK NIH HHS K23 DK123406NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK108670NIDDK NIH HHS R21 DK118927
6 · The paper itself

Abstract

backgroundVedolizumab, an α4β7 integrin antagonist, is an effective therapy for Crohn's disease (CD). Biomarkers are needed to guide therapy and predict outcomes. This study evaluated biomarker concentrations and outcomes in patients with CD undergoing vedolizumab treatment.

methodsSera at weeks 0, 2, 6, 14, and ⩾26 were collected from vedolizumab-treated, refractory CD patients. Concentrations of soluble (s)-Vascular Cell Adhesion Molecule (VCAM)-1, s-Intercellular Cell Adhesion Molecule (ICAM)-1, s-Mucosal Addressin Cell Adhesion Molecule (MAdCAM)-1, and s-α4β7 integrin were evaluated for associations with achieving endoscopic remission.

resultsA total of 22 patients with CD were included. In all patients, s-MAdCAM-1 decreased significantly and s-α4β7 increased compared with baseline. s-VCAM-1 and s-ICAM-1 changed differentially in patients who achieved remission. At week 6, median s-VCAM-1 (859.6 ng/ml

conclusionIn all vedolizumab-treated CD patients, s-MAdCAM-1 decreased significantly and s-α4β7 increased. However, higher concentrations of s-ICAM-1 and s-VCAM-1 at week 6 and lower concentrations of s-α4β7 at week 14 differentiated patients who achieved endoscopic remission. These findings may help identify early predictors of response to vedolizumab treatment in patients with CD. Further validation in less refractory CD patients is needed.

Indexed as

biologicbiomarkermucosal healingpredictvedolizumab

Identifiers

PMID33240396
PMCPMC7675888
OpenAlexW3105007182

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.